It isn’t entirely clear why the efficacy ... least two years. Pfizer executives, meanwhile, pledged to increase their shot’s market share during a January investor call. Moderna has said ...

according to Pfizer. Administering a third dose restores protective efficacy back up to 95% or more, it said. Meanwhile, Moderna also reported new data with its mRNA-1273 jab – which won't be ...

#TeamPfizer and #TeamModerna are two of the captions often found next to selfies of proud newly vaccinated people on social media. And both groups do have a reason to celebrate as the two mRNA ...

Pfizer has said it plans to seek U.S. authorization for a third shot later this month. Moderna President Stephen Hoge said in an interview that the 93% efficacy data covers through March of this year.

Moderna and Pfizer have both said that updated versions ... led to concerns that the current generation of shots may lack efficacy. It's encouraging, then, that Moderna's mRNA-1273.715 vaccine ...

Most experts had hoped for 70% efficacy or higher ... of the leading vaccines require two shots. Pfizer's doses are given three weeks apart, while Moderna and AstraZeneca's are administered ...

The FDA instead reviewed data that Pfizer and Moderna had collected from clinical studies of the safety and efficacy of earlier iterations of the shot, which had been targeted at the original Omicron ...

(Bloomberg) -- Moderna Inc. fell the most in nearly a month after data on the company’s RSV vaccine showed it may not protect people as long as competing shots. Follow-up data from Moderna’s ...

The stellar efficacy and safety profile of ... by other innovative vaccines (GSK's Shingrix, Pfizer's Prevnar) launched in recent years. Moderna's platform technology allows new genetic sequences ...